$MBIO News

Mustang Bio (MBIO) Stock Explodes 260% After FDA Grants Key Cancer Drug Designation

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma

Mustang Bio shares are trading higher after the company was granted FDA Orphan Drug Designation for MB-101 in astrocytomas and glioblastoma.

Mustang Bio shares are trading higher after the company was granted FDA Orphan Drug Designation for MB-101 in astrocytomas and glioblastoma.

Mustang Bio Granted FDA Orphan Drug Designation For MB-101 In Astrocytomas And Glioblastoma

Mustang Bio shares are trading higher after the company announced it received FDA Orphan Drug designation status for MB-101.

Mustang Bio Receives FDA Orphan Drug Designation For MB-101 Treatment Of Malignant Glioma

Mustang Bio Designated Orphan Designation Status For "an autologous ex vivo expanded cluster of differentiation 62-enriched naive and memory T-cell investigational product that has been genetically modified using a self-inactivating lentiviral vector to express an IL13Ralpha2-targeted, hinge-optimized, 4-1BB-costimulatory chimeric antigen receptor with a truncated CD19" For The Treatment Of Malignant Glioma

Mustang Bio Announces Reverse Stock Split

Mustang Bio’s MB-108 receives FDA orphan drug status for glioma treatment

MindBio’s Promising Results in Depression Treatment

Mustang Bio Secures $4M through Strategic Warrant Agreement

MindBio Advances Cancer Anxiety and Depression Trials

MindBio Advances Depression Trials with Promising Results

Mustang Bio treatment of malignant glioma granted FDA orphan status

MindBio Therapeutics to Issue Securities for Fundraising

Mindbio’s Breakthrough in Microdosing for Mental Health

Mustang Bio rating placed under review at H.C. Wainwright

MindBio’s LSD Microdosing Shows Lasting Depression Relief

MindBio Announces Sustained Antidepressant Response 3-Months Post Treatment in Microdosing Depression Clinical Trials